Following on from her presentation during Bridge Life Sciences inaugural 'Targeting Cancer' webinar, our CEO Dr Nicole van der Weerden was back with Chris Kallos, CFA and Jane Lowe on Monday 16 November talking more in depth about Arovella’s cell therapy platform.
Key discussion points include:
Clinical updates on lead blood cancer program ALA-101
Expansion opportunities into autoimmune diseases
Preclinical progress for solid tumour program ALA-105
Funding runway and key milestones over the next 12 months